Overview

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Status:
Completed
Trial end date:
2015-02-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease (CD).
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
AstraZeneca